Synthekine logo

Synthekine Funding & Investors

Synthekine is an engineered cytokine therapeutics company developing disease-optimized treatments. The company uses immunological insights to guide targeted protein engineering to generate transformative medicines for cancer and autoimmune disorders. Using the principles of cytokine partial agonism and immunological specificity, Synthekine designs differentiated therapeutics to be both safe and efficacious. Its lead programs have shown promising efficacy and tolerability in preclinical studies, and it is developing additional cytokine partial agonists that selectively modulate key pathways of the immune system.

synthekine.com

Total Amount Raised: $289,500,000

Synthekine Funding Rounds

  • Series C

    $100,000,000

    Series C Investors

    Column Group
  • Series B

    $107,500,000

    Series B Investors

    Deerfield Management
    Henderson Global Investors
    Emerson Collective
    TCG Crossover Management
    Samsara BioCapital
    Canaan Partners
    Omega Funds
    Lilly Asia Ventures
    Column Group
    Rock Springs Capital
    Ra Capital Management
  • Series A

    $82,000,000

    Series A Investors

    Canaan Partners
    Samsara BioCapital
    Column Group
Funding info provided by Diffbot.